Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries. Under the assigned exclusive license, Everest Medicines will make an upfront payment of US$7 million (equivalent to approximately RMB49.7 million) and...
MANILA, Philippines, Jan. 14, 2025 /PRNewswire/ -- UNI-PIPC (UNI-President Information Philippines Corp.), a new IT solutions provider and subsidiary of Uni-President Group., today announced...
Local artist Vika Cheng meticulously designed and handcrafted giant paper coloured carp to send blessings to the public
The installation features interactive...
KUALA LUMPUR, Malaysia, Jan. 14, 2025 /PRNewswire/ -- The Malaysian Society for Quality in Health (MSQH), a leading national healthcare accreditation body dedicated to...
HO CHI MINH CITY, Vietnam, Jan. 14, 2025 /PRNewswire/ -- GlobalTix, Asia's leading ticketing and marketplace distribution platform, has been named "Growth Partner of...
MELBOURNE, Australia, Jan. 14, 2025 /PRNewswire/ -- As Australia's retail trading market matures, the focus is shifting beyond regulatory compliance to a broader culture...